CRL — Charles River Laboratories International Cashflow Statement
0.000.00%
Last trade - 00:00
- $11.75bn
- $14.14bn
- $4.13bn
- 90
- 40
- 87
- 83
2019 December 28th | 2020 December 26th | 2021 December 25th | 2022 December 31st | 2023 December 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 254 | 365 | 399 | 493 | 480 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 44.5 | -27.2 | 77.5 | 11.6 | 42.7 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 6.18 | -26.3 | 42.9 | -153 | -102 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 481 | 547 | 761 | 620 | 684 |
Capital Expenditures | -141 | -167 | -229 | -325 | -319 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -541 | -435 | -1,209 | -283 | -245 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -682 | -602 | -1,438 | -608 | -563 |
Financing Cash Flow Items | -18.4 | -5.95 | -40.6 | -48.6 | -11.6 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 232 | 47.2 | 673 | -42.4 | -85.5 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 42.7 | -6.93 | 13.2 | -5.1 | 43.3 |